Article thumbnail

A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death

By Carla Lucia Esposito, Diana Passaro, Immacolata Longobardo, Gerolama Condorelli, Pina Marotta, Andrea Affuso, Vittorio de Franciscis and Laura Cerchia


Nucleic acid aptamers have been developed as high-affinity ligands that may act as antagonists of disease-associated proteins. Aptamers are non immunogenic and characterised by high specificity and low toxicity thus representing a valid alternative to antibodies or soluble ligand receptor traps/decoys to target specific cancer cell surface proteins in clinical diagnosis and therapy. The epidermal growth factor receptor (EGFR) has been implicated in the development of a wide range of human cancers including breast, glioma and lung. The observation that its inhibition can interfere with the growth of such tumors has led to the design of new drugs including monoclonal antibodies and tyrosine kinase inhibitors currently used in clinic. However, some of these molecules can result in toxicity and acquired resistance, hence the need to develop novel kinds of EGFR-targeting drugs with high specificity and low toxicity. Here we generated, by a cell-Systematic Evolution of Ligands by EXponential enrichment (SELEX) approach, a nuclease resistant RNA-aptamer that specifically binds to EGFR with a binding constant of 10 nM. When applied to EGFR-expressing cancer cells the aptamer inhibits EGFR-mediated signal pathways causing selective cell death. Furthermore, at low doses it induces apoptosis even of cells that are resistant to the most frequently used EGFR-inhibitors, such as gefitinib and cetuximab, and inhibits tumor growth in a mouse xenograft model of human non-small-cell lung cancer (NSCLC). Interestingly, combined treatment with cetuximab and the aptamer shows clear synergy in inducing apoptosis in vitro and in vivo. In conclusion, we demonstrate that this neutralizing RNA-aptamer is a promising bio-molecule that can be developed as a more effective alternative to the repertoire of already existing EGFR-inhibitors

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS One 3: e1643.
  2. (2007). A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
  3. (2005). Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain.
  4. (2007). Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
  5. (2010). Aptamer-targeted cell-specific RNA interference.
  6. (2009). Cell-specific aptamers for targeted therapies.
  7. (2004). Common and distinct elements in cellular signaling via EGF and FGF receptors.
  8. (2005). Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations.
  9. (2009). Differential SELEX in human glioma cell lines.
  10. (2010). Directed evolution of gold nanoparticle delivery to cells.
  11. (2009). EGFR Signaling and Drug Discovery.
  12. (2010). Ellington A
  13. (1999). ErbB Receptorinduced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases.
  14. (2005). ErbB receptors and cancer: the complexity of targeted inhibitors.
  15. (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.
  16. (1993). Expression and amplification of cyclin genes in human breast cancer.
  17. (2010). From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.
  18. (2007). Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy.
  19. (2011). Inhibition of Cell Proliferation by an Anti-EGFR Aptamer.
  20. (2002). Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor.
  21. (2008). Mechanisms of acquired resistance to cetuximab: role of her (ErbB) family members.
  22. (2010). Mechanisms of resistance to HER family targeting antibodies.
  23. (1987). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.
  24. (2008). PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer.
  25. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
  26. (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro.
  27. (2009). Resistance mechanisms of tumour cells to EGFR inhibitors.
  28. (2006). Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 29-hydroxyl uridines in immune responses.
  29. (2005). Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
  30. (2010). Surface-Immobilized Aptamers for Cancer Cell Isolation and Microscopic Cytology.
  31. (2005). Targeted therapies for non-small cell lung cancer.
  32. (2010). Targeting cancer cells with nucleic acid aptamers.
  33. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer.
  34. (2008). The ERBB3 receptor in cancer and cancer gene therapy.
  35. (2009). Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis.
  36. (2001). Untangling the ErbB signalling network.